An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
Vifor Pharma announced the appointment of Hervé Gisserot as Chief Commercial Officer, effective January 17, 2022. Gisserot, formerly of GlaxoSmithKline, brings extensive experience in commercial leadership across various regions, focusing on sales, marketing, and market access. Under his leadership, various commercial roles will report directly to him, enhancing commercial execution. This aligns with plans to launch four pipeline products within the next 18 months, aiming to maximize the company's iron portfolio.
Positive
Appointment of Hervé Gisserot expected to strengthen commercial leadership and execution.
Gisserot's experience in launching products may enhance pipeline success and market access.
Preparation for the launch of four pipeline products indicates growth potential.
Negative
Transition to new leadership may create continuity concerns within the organization.
Dependence on successful product launches in a competitive market introduces risks.
Hervé Gisserot will join Vifor Pharma as Chief Commercial Officer on 17 January 2022
Responsibilities of Sales, Marketing and Market Access to be streamlined under Chief Commercial Officer role to prioritize commercial execution
ST. GALLEN, Switzerland--(BUSINESS WIRE)--
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma Group today announced the appointment of Hervé Gisserot as Chief Commercial Officer and member of the Vifor Pharma Executive Committee as of 17 January 2022.
Hervé Gisserot, a French citizen, is an experienced industry executive and has a proven track record of building and leading organizations across the U.S., Europe and Asia Pacific with extensive launch and market access experiences. He joins from GlaxoSmithKline where he served in multiple Senior Vice President roles in the last 13 years. He is a graduate of the Institute of Political Science Paris (IEP), and has completed the General Management program at INSEAD.
With this new appointment, the President US, the Regional Commercial Heads, the Rare Disease BU, the central commercial, marketing and pricing teams, will report to the Chief Commercial Officer. This is to lead the organization ahead of expected approvals and subsequent launches of four pipeline products in the next 18 months, and to maximize opportunities of our iron portfolio.
Abbas Hussain, Chief Executive Officer of Vifor Pharma Group, commented: “I am delighted that Hervé joins Vifor Pharma. He brings a wealth of commercial experience from leading pharmaceutical companies at an international level, delivering profitable growth across multiple therapeutic areas and markets. His professional background makes him ideally suited to lead the commercial organization and to put a strong focus on execution as we accelerate growth to become a multi-brand organization focused on in-licensing, partnering and commercializing products worldwide.”
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
Media Relations
Nathalie Ponnier
Global Head Corporate Communications +41 79 957 96 73
media@viforpharma.com
Investor Relations
Julien Vignot
Head of Investor Relations
+41 58 851 66 90
investors@viforpharma.com
Source: Vifor Pharma
FAQ
Who is Hervé Gisserot and what is his role at Vifor Pharma?
Hervé Gisserot is the newly appointed Chief Commercial Officer at Vifor Pharma, effective January 17, 2022, responsible for sales, marketing, and market access.
What are Hervé Gisserot's qualifications?
Gisserot has extensive experience in the pharmaceutical industry, previously holding Senior Vice President roles at GlaxoSmithKline and graduating from the Institute of Political Science Paris and completing a General Management program at INSEAD.
What impact does Gisserot's appointment have on Vifor Pharma's strategy?
His appointment is aimed at streamlining commercial operations and enhancing execution in anticipation of launching four pipeline products over the next 18 months.
When will Gisserot officially start his role at Vifor Pharma?
Hervé Gisserot will officially take on the role of Chief Commercial Officer on January 17, 2022.
What products are expected to launch under Vifor Pharma's pipeline?
Vifor Pharma is preparing for the launch of four pipeline products within the next 18 months, focusing on their iron portfolio.
